Related Experiment Video
Updated: May 8, 2026

Dissection of Single Skeletal Muscle Fibers for Immunofluorescent and Morphometric Analyses of Whole-Mount Neuromuscular Junctions
Published on: August 14, 2021
Myasthenia gravis and the neuromuscular junction
1Neuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain.
Recent advances in understanding autoimmune myasthenia gravis reveal new genetic and environmental risk factors. Novel therapies targeting specific immune pathways offer improved treatment options for this neuromuscular junction disease.
Area of Science:
- Neurology
- Immunology
- Genetics
Background:
- Myasthenic disorders affect the neuromuscular junction with diverse genetic and autoimmune causes.
- Autoimmune myasthenia gravis (MG) pathogenesis is complex and multifactorial.
Purpose of the Study:
- To review recent findings on risk factors, pathogenesis, and treatment of autoimmune myasthenia gravis.
- To highlight advancements in understanding MG and their therapeutic implications.
Main Methods:
- Review of current literature on myasthenia gravis.
- Analysis of recent epidemiological, genetic, and immunological findings.
- Evaluation of emerging therapeutic strategies and their efficacy.
Main Results:
- Identification of new epidemiological and genetic risk factors for MG.
- Elucidation of innate immunity pathways and the role of IgG4 anti-MuSK antibodies.
- Demonstration of efficacy for rituximab in MuSK MG and eculizumab in refractory AChR MG.
Conclusions:
- Growing knowledge of risk factors and immunopathogenesis supports novel biological agents for MG.
- Current immunotherapies offer benefits but require further controlled trials to confirm efficacy and manage side effects.
- Tailored therapeutic algorithms based on MG subtypes are essential for optimal patient outcomes.
More Related Videos
11:03Characterization of Neuromuscular Junctions in Mice by Combined Confocal and Super-Resolution Microscopy
Published on: December 8, 2021
12:18The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy
Published on: December 26, 2014
Related Concept Videos
Myasthenia Gravis ll: Pathophysiology
The Neuromuscular Junction
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Neuromuscular Junction And Blockade